- Home
- Publications
- Publication Search
- Publication Details
Title
RNA Interference of Human α-Synuclein in Mouse
Authors
Keywords
-
Journal
Frontiers in Neurology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-01-31
DOI
10.3389/fneur.2017.00013
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Viral vectors for therapy of neurologic diseases
- (2017) Sourav R. Choudhury et al. NEUROPHARMACOLOGY
- RNAi prevents and reverses phenotypes induced by mutant human ataxin-1
- (2016) Megan S. Keiser et al. ANNALS OF NEUROLOGY
- α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era
- (2016) Naomi P. Visanji et al. TRENDS IN NEUROSCIENCES
- Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons
- (2015) D. Caudal et al. EXPERIMENTAL NEUROLOGY
- shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model
- (2015) Alevtina D. Zharikov et al. JOURNAL OF CLINICAL INVESTIGATION
- Disease-modifying therapeutic directions for Lewy-Body dementias
- (2015) Qiang Zhang et al. Frontiers in Neuroscience
- Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: Positive and negative effects
- (2014) Christina E. Khodr et al. BRAIN RESEARCH
- Synucleins Regulate the Kinetics of Synaptic Vesicle Endocytosis
- (2014) K. J. Vargas et al. JOURNAL OF NEUROSCIENCE
- Broad Therapeutic Benefit After RNAi Expression Vector Delivery to Deep Cerebellar Nuclei: Implications for Spinocerebellar Ataxia Type 1 Therapy
- (2014) Megan S Keiser et al. MOLECULAR THERAPY
- Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease
- (2013) Nandakumar S. Narayanan et al. REVIEWS IN THE NEUROSCIENCES
- Alpha-Synuclein Expression in Patients with Parkinson's Disease: A Clinician's Perspective
- (2013) Han-Joon Kim Experimental Neurobiology
- Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity
- (2012) Meret Nora Gaugler et al. ACTA NEUROPATHOLOGICA
- α-Synuclein knockout mice have cognitive impairments
- (2012) V.S. Kokhan et al. BEHAVIOURAL BRAIN RESEARCH
- Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice
- (2012) Kelvin C. Luk et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice
- (2012) Marie-Francoise Chesselet et al. Neurotherapeutics
- siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse
- (2012) Ryan L. Boudreau et al. NUCLEIC ACIDS RESEARCH
- Prefrontal D1 dopamine signaling is required for temporal control
- (2012) N. S. Narayanan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pathological -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
- (2012) K. C. Luk et al. SCIENCE
- -Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
- (2012) M. Decressac et al. Science Translational Medicine
- A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons
- (2011) Ye Han et al. BRAIN RESEARCH
- An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons
- (2011) Christina E. Khodr et al. BRAIN RESEARCH
- Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease
- (2011) Ryan L Boudreau et al. MOLECULAR THERAPY
- Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease
- (2011) Jodi L McBride et al. MOLECULAR THERAPY
- Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons
- (2011) M. Decressac et al. NEUROBIOLOGY OF DISEASE
- Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease
- (2010) Shuwen Cao et al. Molecular Neurodegeneration
- In Vivo RNAi-Mediated α-Synuclein Silencing Induces Nigrostriatal Degeneration
- (2010) Oleg S Gorbatyuk et al. MOLECULAR THERAPY
- Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis
- (2010) Venu M. Nemani et al. NEURON
- α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra
- (2010) Alison L. McCormack et al. PLoS One
- Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice
- (2009) Ryan L Boudreau et al. MOLECULAR THERAPY
- Tests to assess motor phenotype in mice: a user's guide
- (2009) Simon P. Brooks et al. NATURE REVIEWS NEUROSCIENCE
- Strengths and limitations of genetic mouse models of Parkinson's disease
- (2008) Marie-Francoise Chesselet et al. PARKINSONISM & RELATED DISORDERS
- Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi
- (2008) J. L. McBride et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice
- (2007) Daniel Alvarez-Fischer et al. EXPERIMENTAL NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started